Dispenzieri, Angela http://orcid.org/0000-0001-8780-9512
Coelho, Teresa
Conceição, Isabel
Waddington-Cruz, Márcia
Wixner, Jonas
Kristen, Arnt V.
Rapezzi, Claudio
Planté-Bordeneuve, Violaine
Gonzalez-Moreno, Juan
Maurer, Mathew S.
Grogan, Martha
Chapman, Doug
Amass, Leslie
Pavia, Pablo Garcia
Tarnev, Ivaylo
Costello, Jose Gonzalez
Briseno, Maria Alejandra Gonzalez Duarte
Schmidt, Hartmut
Drachman, Brian
Barroso, Fabio Adrian
Yamashita, Taro
Lairez, Olivier
Sekijima, Yoshiki
Vita, Giuseppe
Jeon, Eun-Seok
Hanna, Mazen
Slosky, David
Luigetti, Marco
LoRusso, Samantha
Beamud, Francisco Munoz
Adams, David
Moelgaard, Henning
Press, Rayomand
Cirami, Calogero Lino
Nienhuis, Hans
Plana, Josep Maria Campistol
Inamo, Jocelyn
Jacoby, Daniel
Emdin, Michele
Quan, Dianna
Hummel, Scott
Witteles, Ronald
Dori, Amir
Shah, Sanjiv
Lenihan, Daniel
Azevedo, Olga
Murali, Srinivas
Zivkovic, Sasa
Low, Soon Chai
Nativi-Nicolau, Jose
Fine, Nowell
Tallaj, Jose
Tschoepe, Carsten
Torrón, Roberto Fernandéz
Polydefkis, Michael
Merlini, Giampaolo
Badelita, Sorina
Gottlieb, Stephen
Tauras, James
Correia, Edileide Barros
Ventura, Hector
Gess, Burkhard
Darstein, Felix
Oh, Jeeyoung
Marburger, Tessa
Van Cleemput, Johan
Salutto, Valeria Lujan
Parman, Yesim
Chao, Chi-Chao
Sarswat, Nitasha
Mueller, Christopher
Steidley, David
Ralph, Jeffrey
Warner, Alberta
Cotts, William
Hoffman, James
Rugiero, Marcelo
Misawa, Sonoko
Blanco, Jose Luis Munoz
Davila, Lucia Galan
Sadeh, Menachem
Luo, Jin
Kyriakides, Theodoros
Wang, Annabel
Kaufmann, Horacio
Zivkovic, Sasa
,
Funding for this research was provided by:
Pfizer
Article History
Received: 5 January 2022
Accepted: 8 May 2022
First Online: 18 June 2022
Declarations
:
: All THAOS sites received ethical or institutional review board approval prior to patient enrollment, and each patient provided written informed consent. The study followed the Good Pharmacoepidemiology Practice guidelines and the principles of the Declaration of Helsinki.
: Not applicable.
: AD reports research grants from Celgene, Millennium, Pfizer, Janssen, and Alnylam; and has received funding from Pfizer for meeting expenses (travel) and attended advisory boards for Akcea and Intellia. TC reports serving as a medical advisor for Pfizer and receiving funding for scientific meeting expenses (travel, accommodation, and registration) from Pfizer. IC reports consulting fees and funding for scientific meeting expenses (travel, accommodation, and registration) from Pfizer. MW-C reports research funding, consulting fees, and travel support for advisory boards and meetings from FoldRx Pharmaceuticals and Pfizer. JW reports consulting fees and travel support for lectures and advisory boards from Pfizer and Alnylam, and consulting fees from Akcea. AVK reports reimbursement for study visits from Pfizer during the conduct of the study. CR reports research grants from Pfizer and consultancy fees from Pfizer, Alnylam, and Prothena. VP-B reports serving as a medical advisor for Pfizer, Alnylam, Eidos, and Ionis. JG-M reports speaker fees from Pfizer, Alnylam, and Akcea. MSM reports grants from Pfizer during the conduct of the study; grants and personal fees from Pfizer, Eidos, Prothena, and Ionis; grants from Alnylam; and personal fees from GSK and Akcea outside the submitted work. MG reports grants and advisory board and consultancy fees paid to her institution from Alnylam, Eidos, Prothena, and Pfizer. DC and LA are full-time employees of Pfizer and hold stock and/or stock options with Pfizer.